Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.43 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2422071 | 1.00 | BIRC2 (0.47) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL2418461 | 1.00 | BIRC2 (0.47) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL18150389 | 0.98 | BIRC2 (0.46) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| Hydrochloric Acid SCHEMBL4223891 | 0.98 | BIRC2 (0.46) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL15105232 | 0.88 | BIRC2 (0.40) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL15105233 | 0.88 | BIRC2 (0.40) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL28120270 | 0.84 | BIRC2 (0.49) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL28048803 | 0.84 | BIRC2 (0.49) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL27957087 | 0.84 | BIRC2 (0.49) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL190024 | 0.83 | BIRC2 (0.47) | BIRC2HRH4CHRNB2CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-20240294550-A1 | 8-OXA-3-AZABICYCLO[3.2.1]OCTANE COMPOUNDS OR SALT THEREOF, AND PREPARATION METHOD AND USE THEREOF | LITTDD MEDICINES LTD (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4378943-A1 | 8-OXO-3-AZABICYCLO[3.2.1]OCTANE COMPOUND OR SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Littdd Medicines Ltd (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-118043325-A | 8-Oxo-3-azabicyclo [3.2.1] octane compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4359081-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | Novartis AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| CN-117425649-A | Pyrazole derivatives as KRAS mutein inhibitors | 诺华股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
| CN-115677730-A | 8-oxygen-3-azabicyclo [3.2.1] octane compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2022269508-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | NOVARTIS AG (CH) | 2022-12-29 | — | — | WO | disclosed |
| US-10988467-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2021-04-27 | — | — | US | disclosed |
| WO-2008136756-A1 | PYRROLOPYRIMIDIN-7-ONE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| US-7354946-B2 | prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-08 | — | — | US | disclosed |
| US-7354946-B2 | prominent growth inhibitory activity against tumor cells; cyclin dependent kinase inhibitors; colon cancer; N'-(3-t-butylisoindolino[3,2-b]oxazolidin-4-on-8-yl)-N-(4-(N-benzylpyrrolidin-3-yl)pyridin-2-yl)urea | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-08 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-4560755-A | VASODILATOR, HYPOTENSOR | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-12-24 | — | — | US | disclosed |
| US-4525589-A | Isoquinolinesulfonyl derivatives | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-06-25 | — | — | US | disclosed |
| EP-0061673-B1 | ISOQUINOLINESULFONYL DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1984-10-24 | — | — | EP | disclosed |
| US-4456757-A | MUSCLE RELAXANTS, VASODILATORS, HYPOTENSIVE AGENTS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1984-06-26 | — | — | US | disclosed |
| EP-0061673-A1 | Isoquinolinesulfonyl derivatives and process for the preparation thereof | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294550-A1 | 8-OXA-3-AZABICYCLO[3.2.1]OCTANE COMPOUNDS OR SALT THEREOF, AND PREPARATION METHOD AND USE THEREOF | ATR, OGG1, ATRIP | BIRC2 717/4885HRH4 4767/4885CHRNB2 2288/4885 |
| US-10988467-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | BIRC2 4456/4885HRH4 253/4885CHRNB2 93/4885 |
| US-20070027147-A1 | Biarylurea derivatives | CDK6, CDK4, CCNI | BIRC2 1198/4885HRH4 745/4885CHRNB2 4758/4885 |
| US-20240317721-A1 | PYRAZOLYL DERIVATIVES AS INHIBITORS OF THE KRAS MUTANT PROTEIN | KRAS, NRAS, APC | BIRC2 1238/4885HRH4 2115/4885CHRNB2 4860/4885 |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BIRC2, BIRC3, API5 | BIRC2 1/4885HRH4 824/4885CHRNB2 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.